Trial Profile

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darolutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Pharmacokinetics
Acronyms Daro-PET

Most Recent Events

27 Jan 2024 According to Trial design presented at the 2024 Genitourinary Cancers Symposium, as of September 20th, 1 patient was included in the study
27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
03 Aug 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com